Zibotentan is a medication being studied for its potential to help manage fluid retention in patients with cirrhosis. It is being tested both on its own and in combination with another medication to see how it affects body weight, body water volumes, and body fat mass. The study also looks at how it influences the use of other diuretics and blood pressure.

Dapagliflozin is another medication involved in the study, used in combination with zibotentan. It is being evaluated for its effectiveness in managing fluid retention and its impact on body weight, body water volumes, and body fat mass in patients with cirrhosis. The combination is also assessed for its effects on the use of other diuretics and blood pressure.

Cirrhosis of the liver – Cirrhosis of the liver is a condition in which the liver becomes scarred and damaged over time. This scarring is often the result of long-term liver damage from various causes, such as chronic alcohol use or viral hepatitis. As the liver tissue becomes increasingly scarred, it loses its ability to function properly. This can lead to complications like fluid retention, jaundice, and increased risk of infections. The progression of cirrhosis can vary, but it generally worsens over time if the underlying cause is not addressed. The liver’s ability to regenerate is impaired, making it difficult for the organ to recover fully.